Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

被引:1
|
作者
Chiang, Ting-Yu [1 ]
Hsu, Hung-Chih [2 ]
Chern, Yih-Jong [3 ]
Liao, Chun-Kai [3 ]
Hsu, Yu-Jen [3 ]
Tsai, Wen-Sy [3 ]
Hsieh, Pao-Shiu [3 ]
Lin, Yu-Fen [1 ]
Lee, Hsiu-Lan [1 ]
You, Jeng-Fu [3 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Nursing, Taoyuan 33305, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Div Hematol Oncol, Taoyuan 33305, Taiwan
[3] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Surg,Div Colon & Rectal Surg, Taoyuan 33305, Taiwan
关键词
metastatic CRC; mCRC; skin toxicity; survival; anti-EGFR; QUALITY-OF-LIFE; PANITUMUMAB; MANAGEMENT; THERAPY; IMPACT; TRIAL;
D O I
10.3390/cancers15061663
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50-70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
    Cardone, Claudia
    Blauensteiner, Bernadette
    Moreno-Viedma, Veronica
    Martini, Giulia
    Simeon, Vittorio
    Vitiello, Pietro P.
    Ciardiello, Davide
    Belli, Valentina
    Matrone, Nunzia
    Troiani, Teresa
    Morgillo, Floriana
    Marino, Federica Zito
    Dentice, Monica
    Nappi, Annarita
    Boccaccino, Alessandra
    Antoniotti, Carlotta
    Cremolini, Chiara
    Pietrantonio, Filippo
    Prager, Gerald W.
    Normanno, Nicola
    Maiello, Evaristo
    Argiles, Guillem
    Elez, Elena
    Signoriello, Giuseppe
    Franco, Renato
    Falcone, Alfredo
    Tabernero, Josep
    Sibilia, Maria
    Ciardiello, Fortunato
    Martinelli, Erika
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : 1 - 10
  • [12] Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020
    Gilabert, Marine
    Ries, Pauline
    Chanez, Brice
    Triby, Simon
    Francois, Eric
    Lievre, Astrid
    Rousseau, Frederique
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1229 - 1236
  • [13] IMMUNOLOGICAL EFFECTS OF DIFFERENT ANTI-EGFR ANTIBODIES IN METASTATIC COLORECTAL CANCER PATIENTS
    Manzoni, M.
    Delfanti, S.
    Rovati, B.
    Brugnatelli, S.
    Ronzoni, M.
    Perfetti, V
    Mariucci, S.
    Loupakis, F.
    Danova, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 33 - 33
  • [14] An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
    Rosati, Gerardo
    Montrone, Michele
    Pacilio, Carmen
    Colombo, Alfredo
    Cicero, Giuseppe
    Paragliola, Fernando
    Vaia, Angelo
    Annunziata, Luigi
    Bilancia, Domenico
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [15] MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
    Mosakhani, Neda
    Lahti, Leo
    Borze, Ioana
    Karjalainen-Lindsberg, Marja-Liisa
    Sundstrom, Jari
    Ristamaki, Raija
    Osterlund, Pia
    Knuutila, Sakari
    Sarhadi, Virinder Kaur
    CANCER GENETICS, 2012, 205 (11) : 545 - 551
  • [16] A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients
    Bonin, Serena
    Donada, Marisa
    Bussolati, Gianni
    Nardon, Ermanno
    Annaratone, Laura
    Pichler, Martin
    Chiaravalli, Anna Maria
    Capella, Carlo
    Hoefler, Gerald
    Stanta, Giorgio
    TUMOR BIOLOGY, 2016, 37 (06) : 7295 - 7303
  • [17] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
    Yang, Jiao
    Li, Shuting
    Wang, Biyuan
    Wu, Yinying
    Chen, Zheling
    Lv, Meng
    Lin, Yayun
    Yang, Jin
    TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
  • [18] Current concepts of anti-EGFR targeting in metastatic colorectal cancer
    Doleschal, Bernhard
    Petzer, Andreas
    Rumpold, Holger
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
    Martins, Marta
    Mansinho, Andre
    Cruz-Duarte, Raquel
    Martins, Soraia Lobo
    Costa, Luis
    TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
  • [20] MicroRNA-31 May Predict Response in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR Therapy
    Mitsuhashi, Kei
    Nosho, Katsuhiko
    Igarashi, Hisayoshi
    Ito, Miki
    Naito, Takafumi
    Sukawa, Yasutaka
    Okuda, Hiroyuki
    Yoshii, Shinji
    Kusumi, Takaya
    Hosokawa, Masao
    Yamamoto, Eiichiro
    Suzuki, Hiromu
    Yamamoto, Hiroyuki
    Imai, Kohzoh
    Shinomura, Yasuhisa
    GASTROENTEROLOGY, 2014, 146 (05) : S329 - S330